Quinagolide - Novartis

Drug Profile

Quinagolide - Novartis

Alternative Names: CV 205 502; Norprolac; Prolactin; Quinagolide hydrochloride; SDS-205502; SDZ-205502

Latest Information Update: 07 Oct 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Aminoquinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility; Hyperprolactinaemia; Prolactinoma

Most Recent Events

  • 02 Oct 2018 Ferring Pharmaceuticals plans the phase II RAQUEL trial for Endometriosis in USA (NCT03692403)
  • 07 Oct 2009 Launched for Hyperprolactinaemia in European Union (PO)
  • 07 Oct 2009 Launched for Hyperprolactinaemia in Hong Kong (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top